Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Modulating T-cell homeostasis with IL-7: preclinical and clinical studies.

Capitini CM, Chisti AA, Mackall CL.

J Intern Med. 2009 Aug;266(2):141-53. Review.

2.

Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies.

Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, Dhanji S, Nguyen LT, Gronski MA, Morre M, Assouline B, Lahl K, Sparwasser T, Ohashi PS, Mak TW.

Nat Med. 2009 May;15(5):528-36. doi: 10.1038/nm.1953. Epub 2009 Apr 26. Erratum in: Nat Med. 2009 Jul;15(7):819.

PMID:
19396174
3.

Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma.

Cattaruzza L, Gloghini A, Olivo K, Di Francia R, Lorenzon D, De Filippi R, Carbone A, Colombatti A, Pinto A, Aldinucci D.

Int J Cancer. 2009 Sep 1;125(5):1092-101. doi: 10.1002/ijc.24389.

4.

IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector.

Colombetti S, Lévy F, Chapatte L.

Blood. 2009 Jun 25;113(26):6629-37. doi: 10.1182/blood-2008-05-155309. Epub 2009 Apr 21.

5.

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy.

Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D.

Cancer Res. 2009 May 1;69(9):4010-7. doi: 10.1158/0008-5472.CAN-08-3712. Epub 2009 Apr 21.

6.

Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.

Zhang M, Yao Z, Dubois S, Ju W, Müller JR, Waldmann TA.

Proc Natl Acad Sci U S A. 2009 May 5;106(18):7513-8. doi: 10.1073/pnas.0902637106. Epub 2009 Apr 21.

7.

Interleukin-15 expression affects homeostasis and function of B cells through NK cell-derived interferon-gamma.

Gill N, Paltser G, Ashkar AA.

Cell Immunol. 2009;258(1):59-64. doi: 10.1016/j.cellimm.2009.03.010. Epub 2009 Apr 9.

PMID:
19361783
8.

CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia.

González-García S, García-Peydró M, Martín-Gayo E, Ballestar E, Esteller M, Bornstein R, de la Pompa JL, Ferrando AA, Toribio ML.

J Exp Med. 2009 Apr 13;206(4):779-91. doi: 10.1084/jem.20081922. Epub 2009 Apr 6. Erratum in: J Exp Med. 2009 Jul 6;206(7):1633.

9.

Replicative potential of human natural killer cells.

Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D.

Br J Haematol. 2009 Jun;145(5):606-13. doi: 10.1111/j.1365-2141.2009.07667.x. Epub 2009 Mar 26.

10.

The regulatory function of umbilical cord blood CD4(+) CD25(+) T cells stimulated with anti-CD3/anti-CD28 and exogenous interleukin (IL)-2 or IL-15.

Lee CC, Lin SJ, Cheng PJ, Kuo ML.

Pediatr Allergy Immunol. 2009 Nov;20(7):624-32. doi: 10.1111/j.1399-3038.2008.00843.x. Epub 2009 Feb 28.

PMID:
19302176
11.

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G.

Clin Cancer Res. 2009 Mar 15;15(6):2123-9. doi: 10.1158/1078-0432.CCR-08-2663. Epub 2009 Mar 10.

12.

NK cells recognize and kill human glioblastoma cells with stem cell-like properties.

Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, Moretta A, Corte G, Bottino C.

J Immunol. 2009 Mar 15;182(6):3530-9. doi: 10.4049/jimmunol.0802845.

13.

IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.

Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E.

J Immunol. 2009 Mar 15;182(6):3423-31. doi: 10.4049/jimmunol.0803068.

14.
15.

IL-21 mediates suppressive effects via its induction of IL-10.

Spolski R, Kim HP, Zhu W, Levy DE, Leonard WJ.

J Immunol. 2009 Mar 1;182(5):2859-67. doi: 10.4049/jimmunol.0802978.

16.

IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.

King JW, Thomas S, Corsi F, Gao L, Dina R, Gillmore R, Pigott K, Kaisary A, Stauss HJ, Waxman J.

Clin Cancer Res. 2009 Feb 15;15(4):1145-54. doi: 10.1158/1078-0432.CCR-08-1821.

17.

Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.

Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD.

Cancer Immunol Immunother. 2009 Oct;58(10):1565-76. doi: 10.1007/s00262-009-0666-y. Epub 2009 Feb 6.

18.

Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition.

Khawam K, Giron-Michel J, Gu Y, Perier A, Giuliani M, Caignard A, Devocelle A, Ferrini S, Fabbi M, Charpentier B, Ludwig A, Chouaib S, Azzarone B, Eid P.

Cancer Res. 2009 Feb 15;69(4):1561-9. doi: 10.1158/0008-5472.CAN-08-3198. Epub 2009 Feb 3.

19.

Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells.

Guimond M, Veenstra RG, Grindler DJ, Zhang H, Cui Y, Murphy RD, Kim SY, Na R, Hennighausen L, Kurtulus S, Erman B, Matzinger P, Merchant MS, Mackall CL.

Nat Immunol. 2009 Feb;10(2):149-57. doi: 10.1038/ni.1695. Epub 2009 Jan 11.

20.

Interleukin 7/interleukin 7 receptor induce c-Fos/c-Jun-dependent vascular endothelial growth factor-D up-regulation: a mechanism of lymphangiogenesis in lung cancer.

Ming J, Zhang Q, Qiu X, Wang E.

Eur J Cancer. 2009 Mar;45(5):866-73. doi: 10.1016/j.ejca.2008.12.006. Epub 2009 Jan 10.

PMID:
19136250

Supplemental Content

Support Center